eISSN 2288-3657
pISSN 2288-3649
pISSN 2288-3649
| Baseline characteristics | Median OS (95% CI) |
P (univariate analysis) |
Multivariate analysis | |
|---|---|---|---|---|
| HR (95% CI) | P-value | |||
| Age | 0.009 | 0.73 (0.44-0.91) | 0.019 | |
| <63 | NR (NA) | |||
| ≥63 | 4.4 (3.21-5.59) | |||
| Sex | 0.415 | |||
| Male | 5.0 (4.24-6.76) | |||
| Female | 5.8 (4.87-6.73) | |||
| ECOG PS score | 0.011 | 0.71 (0.39-0.89) | 0.015 | |
| 0 | NR (NA) | |||
| 1-2 | 4.2 (3.15-5.25) | |||
| Smoking history | 0.732 | |||
| Yes | 5.3 (4.22-6.38) | |||
| No | 5.3 (4.19-6.41) | |||
| Histological type | 0.435 | |||
| Adenocarcinoma | 5.5 (4.41-6.59) | |||
| Other type | 5.3 (4.11-6.49) | |||
| Pathological staging | 0.007 | 0.64 (0.32-0.81) | 0.009 | |
| II | NR (NA) | |||
| IIIa | 3.9 (3.02-4.78) | |||
| EGFR gene mutation status | 0.515 | |||
| Positive | 5.5 (4.49-6.51) | |||
| Negative | 5.1 (4.17-6.03) | |||
| Surgical resection type | 0.612 | |||
| Lobectomy | 5.5 (4.31-6.69) | |||
| Pneumonectomy | 5.3 (4.22-6.38) | |||
| Adjuvant chemotherapy regimens | 0.415 | |||
| Cisplatin-based regimen | 5.3 (4.49-6.11) | |||
| Carboplatin-based regimen | 5.3 (4.21-6.39) | |||
| TMB status | 0.014 | 0.74 (0.45-0.92) | 0.025 | |
| TMB-L | NR (NA) | |||
| TMB-H | 4.6 (3.44-5.66) | |||
OS, overall survival; HR, hazard ratio; ECOG, eastern cooperative oncology group; PS, performance status; EGFR, epidermal growth factor receptor; TMB, tumor mutation burden; TMB-L, TMB the low level group; TMB-H, TMB the high level group; NR, not reached; NA, not available.
J Cancer Prev 2023;28:175~184 https://doi.org/10.15430/JCP.2023.28.4.175
© J Cancer Prev
© Korean Society of Cancer Prevention. / Powered by INFOrang Co., Ltd